This study focuses on Interstitial Lung Disease related to systemic sclerosis, a condition where lung tissue becomes scarred and breathing becomes difficult. The study will test a combination of two medications: rituximab and mycophenolate mofetil. The purpose is to evaluate how well this combination treatment works on lung function compared to using mycophenolate mofetil with a placebo.
The treatment involves receiving rituximab through intravenous infusions, while mycophenolate mofetil is taken by mouth. Some participants will receive rituximab with mycophenolate mofetil, while others will receive a placebo with mycophenolate mofetil. Sodium chloride solution will be used for the intravenous administration of medications.
The study will last 48 weeks, during which participants’ lung function will be monitored. Throughout the study, various tests will be performed to check breathing capacity and overall health status. The treatment involves taking mycophenolate mofetil daily and receiving rituximab or placebo at specific times during the study period.
France 
